title: The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients.
abstract: The purpose of the study was to evaluate the influence of baseline haemoglobin level in predicting response to 5-fluorouracil (5FU)-based first-line chemotherapy in advanced colorectal cancer patients. Data from 631 patients were collected from three different institutions. Globally, overall response rate was 35.8% (226 out of 631). Factors influencing response rate were 5FU dose intensity (high: 43.1%, low: 34.0%, P = 0.03); oxaliplatin (yes: 45.8%, no: 22.9%, P < 0.0001), performance status (PS 0: 46.1%, 1: 28.8%, 2: 26.7%, P < 0.0001), and haemoglobin levels (> or = 12 g dl(-1): 40.4%, < 12 g dl(-1): 29.2%, P = 0.004). In subgroup analysis significant differences in response rate between anaemic and nonanaemic patients were recorded in those patients treated with infusional chemotherapies (45.7 vs 25.5%, P < 0.0001), with high 5FU dose intensity (50.3 vs 32.7%, P = 0.005), with PS = 0 (49.8 vs 37.9%, P = 0.03), and with liver metastases (44.8 vs 33.8%, P = 0.002), whereas no difference was evident in those subjects treated with bolus schedules or according to gender. Anaemia was a strong predictor for activity of first-line 5FU-based chemotherapy especially in those groups that showed the best responses, for example high performance status, infusionally treated, higher 5FU dose and those with liver secondaries. Patients with higher haemoglobin levels recorded a greater response rate and a longer time to progression and survival than anaemic subjects. Prospective evaluation of role of correcting anaemia on response to therapy is justified by these results.
authors.affiliation: Department of Medical Oncology, University of Torino, San Luigi Hospital, 10043 Orbassano, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Tampellini
authors.forename: A
authors.initials: A
authors.lastname: Saini
authors.forename: I
authors.initials: I
authors.lastname: Alabiso
authors.forename: R
authors.initials: R
authors.lastname: Bitossi
authors.forename: M P
authors.initials: MP
authors.lastname: Brizzi
authors.forename: C M
authors.initials: CM
authors.lastname: Sculli
authors.forename: A
authors.initials: A
authors.lastname: Berruti
authors.forename: G
authors.initials: G
authors.lastname: Gorzegno
authors.forename: A
authors.initials: A
authors.lastname: Magnino
authors.forename: E
authors.initials: E
authors.lastname: Sperti
authors.forename: S
authors.initials: S
authors.lastname: Miraglia
authors.forename: L
authors.initials: L
authors.lastname: Forti
authors.forename: O
authors.initials: O
authors.lastname: Alabiso
authors.forename: M
authors.initials: M
authors.lastname: Aglietta
authors.forename: A
authors.initials: A
authors.lastname: Harris
authors.forename: L
authors.initials: L
authors.lastname: Dogliotti
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000150:complications; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D016208:Databases, Factual; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis* / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D012044:Regression Analysis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D006454:Hemoglobins; D005472:Fluorouracil